#Japan #Tokyo #Healthcare Data #Real-World Evidence #TXP Medical

Introduction to Real-World Evidence in Japan

TXP Medical Co., Ltd., under the leadership of CEO Tomohiro Sonoo, recently unveiled an enlightening whitepaper titled "The State of Japanese Real-World Evidence (RWE)." The report provides a deep dive into the utilization and implications of real-world data (RWD) and RWE within the Japanese healthcare sphere, marking a significant contribution to medical discourse.

The Growth of the EMR-Derived Data Market

The whitepaper indicates a dramatic rise in the sector for electronic medical record (EMR)-derived data, projected to grow significantly from approximately ¥3.9 billion in 2025 to about ¥25 billion by 2035. This growth occurs alongside a notable increase in the use of RWD/RWE in regulatory approvals, climbing from 18.1% in 2019 to 30.4% in 2024. Such figures outline an evolving healthcare landscape, necessitating a more nuanced understanding of the data sources at medical professionals' disposal.

Background of the Study

With Japan standing as one of the world’s foremost pharmaceutical markets, the potential of its universal health insurance system is immense. It creates a vast pool of longitudinal claims data, encompassing around 120 million individuals. However, the richness of disease-specific information—including biomarkers and treatment rationales—often remains inaccessible through claims data alone. Enhancing these datasets with EMR information is critical to providing clinically relevant evidence.

Current Data Landscape and Future Prospects

As of 2023, Japan observed a 65.6% adoption rate for EMRs across general hospitals, escalating to 93.7% in larger institutions with over 400 beds. The government aims for a fully integrated EMR system by 2030 to facilitate patient data sharing across medical institutions. Nevertheless, secondary utilization of medical information, as sanctioned by the Next Generation Medical Infrastructure Act (NGMIA), remains limited. Currently, there is a modest number of cooperating facilities and certified operator groups.

Key Insights from the Whitepaper

Central to the document are four critical themes intended for pharmaceutical Medical Affairs: 1) understanding patient treatment pathways, 2) quantifying unmet needs, 3) evaluating real-world treatment effectiveness, and 4) generating evidence using hybrid study designs. The whitepaper details the strengths and drawbacks of both claims and EMR data, offering invaluable insights into their practical applications.

EMR Data Distinction

Particularly, EMR data shines when:

• - Analyzing treatment outcomes that are influenced by clinical characteristics unique to the Japanese populace.
• - Navigating Japan's specific reimbursement landscapes and clinical frameworks.
• - Recognizing discrepancies between real-world practices and evidence from international studies.

The document also addresses practical strategies for conducting EMR-based research, such as feasibility evaluations, optimal site selection, and emerging regulatory contexts.

The Role of TXP Medical’s Data Platform

This whitepaper leverages insights from TXP Medical’s robust healthcare data platform, established in collaboration with 56 hospitals throughout Japan, encompassing over 26 million patients and chronicling over 15 years of clinical data. The platform integrates a wide array of clinical notes and crucial lab parameters, providing a comprehensive data foundation for effective medical decision-making.

Leadership and Future Directions

As of October 1, 2026, under the new guidance of Tymo Nakao, Head of Medical Data Lab, TXP Medical is committed to further advancing the understanding and application of RWD and RWE. Dr. Nakao's experience with prestigious healthcare consultancy McKinsey positions TXP Medical advantageously for strategic growth.

Concluding Thoughts

With this whitepaper, TXP Medical aspires to foster informed conversations among Medical Affairs professionals about their evidence strategies, emphasizing a tailored approach combining various data sources to address clinical questions optimally. The ongoing efforts of TXP Medical signal a pivotal shift in Japan’s approach to real-world evidence—a vital evolution for the future of healthcare in the region.